Slide 1: Operating Model Transformation to Accelerate Growth and Promote Agility
Operating Model Transformation to Accelerate Growth and Promote Agility Evotec SE, Horizon Webcast, March 2026
Slide 2: Today's Speakers
Today’s Speakers Christian Wojczewski Horizon Business Details CEO Paul Hitchin Horizon Financial Details CFO Aurélie Dalbiez Q&A Availability CPO PAGE 2
Slide 3: Disclaimer
Disclaimer Cautionary Note Regarding Forward-Looking Statements This presentation (including any information which has been or may be supplied This presentation contains forward-looking statements concerning our business, in writing or orally in connection here with or in connection with any further
Slide 4: Transforming Evotec for Sustainable Growth
Transforming Evotec for Sustainable Growth Multi-stage process initiated with 2024 Priority Reset Stabilization Value Creation 2024 Priority Reset 2026 Horizon Targeted Cost-Out Program Operating Model Transformation • Overachieved ~€40 million savings target • Streamline operations and simplify str
Slide 5: The Post-Pandemic Market
The Post-Pandemic Market Funding levels reset with trend toward clinical-stage investment Biotech funding1 overlayed by Evotec’s stock development 120 Innovation Capital (USDbn) 50 Evotec stock price (EUR) 100 40 Biotech valuations declined 80 30 sector-wide as pandemic-era 60 20 funding normalized
Slide 6: Discovery & Preclinical Development Outlook
Discovery & Preclinical Development Outlook Modest overall R&D growth projections mask early-stage rebound Worldwide Total Pharmaceutical R&D Spend1 In $ billion Largest patent cliff in more than a decade 366 357 348 339 Advances in data science, automation and AI 329 317 306 Ongoing strategic outso
Slide 7: Four Levers of Mid-Term Value Creation
Four Levers of Mid-Term Value Creation Strategy charts path to profitable and sustainable growth 1 Above market growth rates at better-quality earnings 2 Commitment to operational excellence 3 Improved monetization of Just – Evotec Biologics 4 Upside through returns on asset pipeline PAGE 7
Slide 8: Transformation Path
Transformation Path Horizon marks transition from stabilization to intensified value creation Priority Reset Review New Strategy Horizon Sustainable Growth Create more targeted and Strategic review of business Foundation for profitable Transforming operating Focus on optimization cost-efficient busi
Slide 9: Horizon Core Components
Horizon Core Components Improvements across operations, science and commercial execution Reduce global footprint from currently 14 sites to 10 Scientific Leadership sites over the next two years Establish Centers of Excellence to improve scientific depth and partner readiness Operational Excellence
Slide 10: Evotec Global Pre-Transformation Footprint
Evotec Global Pre-Transformation Footprint Duplicated functions across 19 sites* Hamburg Redmond Halle Headquarters J.POD – Development Alderley Park Biology, platforms, Development neuroscience, iPSC and manufacturing Protein science Cyprotex Cologne Göttingen Framingham iPSC Seattle Transcriptomic
Slide 11: Global Post-Horizon Footprint
Global Post-Horizon Footprint Centralized innovation infrastructure focused on 10 sites* Hamburg Redmond Headquarters J.POD – Development Alderley Park Biology, platforms, neuroscience, iPSC and manufacturing Protein science Cyprotex Göttingen Seattle Transcriptomics, Just Evotec Biologics – E.MPD,
Slide 12: Preliminary Unaudited Financial Results for Full-Year 2025
Preliminary Unaudited Financial Results for Full-Year 2025 Final fourth quarter and full-year 2025 reporting scheduled for April 8, 2026 in € m1 Guidance 20252 Group revenues €788 m €760 - 800 m €811 m CER Group Reporting €41 m Adjusted Group EBITDA3 €30 - 50 m €52 m CER in € m D&PD JEB Revenues €52
Slide 13: Horizon Financial Impact and Full-Year 2026 Guidance
Horizon Financial Impact and Full-Year 2026 Guidance Transition period with visible improvements in the second half of 2026 Horizon Financial Impact 2026 Full-Year Guidance Exp. total run-rate cost savings Group Revenues • ~€75 million by end of 2027 • €700-780 million (€730-810 million CER) Exp. to
Slide 14: Enabling Sustainable Growth by 2030
Enabling Sustainable Growth by 2030 New 2026-2030 medium-term framework aligned with transformation roadmap EBITDA margin 20% >20% Revenue CAGR >€1 bn (8-12% CAGR) 2026 2027 2028 2029 2030 Exp. total restructuring cash costs (~€100 m, 2026-2028) Expected total run-rate cost savings (~€75 m by end of
Slide 15: Horizon Overview
Horizon Overview Comprehensive transformation positions Evotec for sustainable mid-term growth Operating model transformation to win in a recovering early-stage discovery market driven by innovation, agility and AI readiness Operations – streamlined footprint for simpler structures and improved cost
Slide 16: Thank you
Thank you Dr. Sarah Fakih EVP Head of Global Communications & Investor Relations +49 (0) 151 7068 8784 (m) sarah.fakih@evotec.com